AZ reported Q1 Orpathys sales up 43% (48% at CER). HCM gets a large % of the revenue in royalties and manufacturing fees.
Sales continue to build after inclusion in NRDL. |
Lauders - the next news I am looking at is 9 May in the Takeda Q4 results. This will show how sales are going in US market.
There are some product approvals due in the next few months. The sNDA for Fruq in GC is probably first, with EMA approval, JPN approval and then Sovlep BTD review all expected this year….not sure how long China regulator is taking on priority reviews, so maybe the ESLIM01 review also sneaks into 2024.
The Sovlep review result was seen as a trigger for partnering negotiations.
I am sure there will be other news but those should be the big ones coming up. An efficient market would be baking in some of these results….but we certainly dont have that so I am hoping the individual approvals will create a variety of bump ups…the market for Fruq controlled by the EMA is 3x the US so is probably the most important, followed by a Sovlep approval and subsequent partnering announcement. |
Are we going to hit the 300p barrier and hopefully push through it this time? Would be great to get some decent news so that it makes it possible and then pushes us through the 400p target I have in mind for starters. We were just under 600p three years ago! |
China Universal Asset Management Co. Ltd. lifted its position in HUTCHMED (China) Limited (NASDAQ:HCM – Free Report) by 353.7% in the fourth quarter, Holdings Channel reports. The firm owned 3,593 shares of the company’s stock after acquiring an additional 2,801 shares during the period. China Universal Asset Management Co. Ltd.’s holdings in HUTCHMED were worth $65,000 as of its most recent filing with the Securities & Exchange Commission.
Could be the reason? More in the link than that shared above, so more interest by more parties in the stock now? |
Anyone know the rise today ? |
More good news from HCM today: HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status |
Yes…sNDA likely approval mid 25 and revenue in H2 25.
Delivering as promised in their target pipeline development slide. |
Good news today but so far only 1% up in HK.
HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC
Further reading of the news states "......has been accepted for review by the China National Medical Products Administration (NMPA). If approved, the new label indication for savolitinib will be expanded to include treatment-naive patients in China.
Hence the more muted response. Still, another step in the right direction. |
Excellent share price performance and I admit I sold close to the bottom after years of frustration although did buy 3NVDL on Jan 2nd which is a 3x Nvidia Leveraged ETF so have done extremely well there. I will put some of my profits back into Hutchmed shortly. |
There does appear to be a growing number of analysts expecting an earnings beat creating an expectation of rising share price |
I am not sure these moves on no news really mean anything…and could well be reversed tomorrow when the market takes fright at some statement coming from US/China that indicates more restrictions.
The next news I will be looking for will be from Takeda…
Their annual results are due in early/mid May and will contain the $15m sales from 2023 disclosed by HCM and the first three months of 2024.
There may have been some stocking within the $15m and conversion of those on early access programs, but I hope they can sell $30m in Q1 and build to a $50m/quarter during 2024. This would give US in market sales of $150-180 and a $20m royalty (pure profit) to HCM (plus manufacturing fees).
It was interesting to see in the company presentation that Europe is potentially a much larger market than the US. It did not appear that the EMA was giving priority status, so they may take longer than the US to approve…that will also be good news when it comes. |
Nice move today. Wish it would continue and some decent news would appear to maintain it! Can dream ;-) |
fantastic results, great progress, one day they may attract a decent valuation; maybe that will be when they start generating free cashflow, but hopefully before that! |
I have stuck with HCM through everything because in the end the story has not changed.
Management has been ropey at times, but they are delivering the products and the cash is now coming in.
Only politics holding them back and they are working their way round that. |
Good results.Little to worry about other than the geopolitically afflicted rating! |
Revenue grew 97%...Strengthened cash balance, with $886.3 million at year end (2022: $631.0m) |
Results tomorrow. |
Looking a bit better. Did we all get a response to emails sent to the co? |
AZ reporting $44m of orpathys sales.
This would imply $30m revenue for HCM as flat on H1. |
I know what you mean NoS, having recently semi-retired….fortunately I don’t have to access my holding here for some time…and I have the option of selling in chunks to give to my kids to put into their LISA…..this company still has a lot to give in the next 10-20 years.
As today’s 10% rise shows this can move quickly upwards…but as we know quickly down too…it is barely believable that all the gain associated with the Takeda deal and FDA approval has evaporated. |
thankyou 1jat, I do think that I will be buying at some stage, possibly later this year if or when the geo-politics issues subside. This is such a great under valued Company. My specific issue is one of oppoertunity cost here and my problem of effectively dead money and I have a specific timeframe to grow my investment and frankly time will run out! |
More positive news yesterday and no positive impact on the share price. HCM really are in a rut at the moment. Thought 2024 was going to be better, but still 11 months to go. |
Register for real-time alerts, custom portfolio, and market movers
Hot Features
Premium
